Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Impact of COVID-19 on HSCT and cellular therapies in the US

Katie Maurer • 2 Feb 2021
TCT 2021
General

Katie Maurer, MD, PhD, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses the impact of the COVID-19 pandemic on hematopoietic stem cell transplantation (HSCT) and immune effector cell therapies at the Dana-Farber Cancer Insitute. In this analysis, Dr Maurer reports that with appropriate safety precautions and screening procedures, HSCT and immune effector cell therapies can be safely administered through the ongoing COVID-19 pandemic. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Katie Maurer

0:49
Advances in GvHD and maintenance following transplant
Katie Maurer • 5 Feb 2021
1:38
Learnings of COVID-19 on transplant and cellular therapies
Katie Maurer • 5 Feb 2021

Related Videos

3:11
Exercise as an underutilized tool in cancer care
Rebecca Robinson • 23 Apr 2024
2:30
The impact of conflict on access to cancer therapies
Richard Sullivan • 29 Apr 2024
2:15
Cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
Arjun Ghosh • 25 Apr 2024
1:09
Rethinking healthcare to improve affordability, sustainability, and patient outcomes
Richard Sullivan • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals